Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

635
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
635
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

726
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
726
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

732
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
732
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

643
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
643
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
528

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TREM2 defends the liver against alveolar echinococcosis by driving fibrous shell formation.

Biochemical pharmacology·2026
Same author

Anion-Solvent Dual-Sieving Effect Revolutionizes Li Deposition Kinetics for Garnet-Based Solid-State Lithium Batteries.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Eco-Corona of Microplastics in Soil Inhibits Their Role as a Contaminant Vector While Enhancing Their Role as a Microorganism Vector.

Environmental science & technology·2026
Same author

Tailoring Solvation Structure via Soft-Hard Segment Synergy in Gel Polymer Electrolytes Enables Dendrite-Free Sodium Batteries with Ultra-Long Cycling.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Loss of ZNRF3/RNF43 unleashes EGFR in cancer.

eLife·2026
Same author

A novel method for establishing a mouse model of hepatic echinococcosis: Ultrasound-guided percutaneous liver puncture modeling.

PLoS neglected tropical diseases·2026

Related Experiment Video

Updated: Jan 17, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.8K

Decoding Barberry Root's Therapeutic Network: A Synergistic Solution for IBS-D.

Qi Yan1, Xufei Wang1, Huijiao Jiang1

  • 1Department of Immunology, School of Medicine, Shihezi University, Shihezi, Xinjiang, China.

Combinatorial Chemistry & High Throughput Screening
|September 18, 2025
PubMed
Summary

Barberry Root (Sankezhen) alleviates diarrhea-predominant irritable bowel syndrome (IBS-D) by reducing inflammation and regulating gut motility. This study identified key compounds and molecular targets, revealing its multi-pathway therapeutic potential.

Keywords:
Barberry rootdiarrhea-predominant irritable bowel syndrome (IBS-D)experimental validationmolecular simulationmulti-target therapy.network pharmacology

More Related Videos

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

1.2K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.3K

Related Experiment Videos

Last Updated: Jan 17, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.8K
Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

1.2K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.3K

Area of Science:

  • Pharmacology
  • Computational Biology
  • Gastroenterology

Background:

  • Diarrhea-predominant irritable bowel syndrome (IBS-D) is a prevalent gastrointestinal disorder.
  • Traditional Uyghur medicine utilizes Barberry Root (Sankezhen, SKZ) for IBS-D treatment.
  • The molecular mechanisms underlying SKZ's efficacy for IBS-D are not well understood.

Purpose of the Study:

  • To computationally predict and experimentally validate the therapeutic targets and molecular pathways of SKZ for IBS-D.
  • To elucidate the synergistic mechanisms of SKZ in alleviating IBS-D symptoms.

Main Methods:

  • Bioactive compounds and targets of SKZ were identified using multiple databases (TCM-Suite, BATMAN-TCM).
  • IBS-D targets were collected from DisGeNET and GeneCards.
  • Network pharmacology (PPI, GO, KEGG) and molecular docking/dynamics simulations were employed.
  • In vitro (macrophages) and in vivo (IBS-D rat model) experiments were conducted for validation.

Main Results:

  • Fifteen active compounds and 85 overlapping targets were identified, prioritizing four key compounds and 15 hub targets.
  • Enrichment analyses indicated SKZ targets are involved in inflammation and intestinal motility pathways.
  • SKZ demonstrated anti-inflammatory effects, downregulated key genes (CHAT, C-FOS, 5-HT3R, 5-HT4R), and inhibited intestinal contractions.

Conclusions:

  • SKZ exhibits synergistic effects in ameliorating IBS-D through multi-pathway regulation.
  • The herb potentially acts via pathways involving inflammation (NF-κB/MAPK), neurotransmission (cholinergic/5-HT), and ion channels.
  • Findings support SKZ's therapeutic role in IBS-D, warranting further investigation of individual compounds.